Compositions containing Patatin-like phospholipase domain-containing protein 3 (PNPLA3) mRNA and methods of using them
Patent Information
- Application Number
- EA202491295
- Authority / Receiving Office
- EA · EA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-06-18
- Filing Date
- 2020-12-14
- Publication Date
- 2026-11-12
- Estimated Expiration
- 2040-12-14
Smart Images

Figure CLAIM-12112026-IMGC0001 
Figure CLAIM-12112026-IMGC0002
Abstract
Claims
1. Double-stranded ribonucleic acid (dsRNA) or its salt for inhibiting the expression of patatin-like phospholipase domain-containing protein 3 (PNPLA3) in a cell, wherein the dsRNA or salt thereof comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises at least 19 contiguous nucleotides, differing by no more than 3 nucleotides from the nucleotide sequence 5'-AUUGGCAUCAAUGAAGGGUACGU-3' (SEQ ID NO:1258), wherein all nucleotides of the sense strand and all nucleotides of the antisense strand contain a nucleotide modification, and wherein at least one chain is conjugated to a ligand.
2. dsRNA or a salt thereof according to claim 1, wherein the antisense strand comprises at least 19 contiguous nucleotides that differ by no more than 2 nucleotides from the nucleotide sequence 5'-AUUGGCAUCAAUGAAGGGUACGU-3' (SEQ ID NO:1258).
3. dsRNA or a salt thereof according to claim 1 or 2, wherein the antisense strand comprises at least 19 contiguous nucleotides that differ by no more than 1 nucleotide from the nucleotide sequence 5'-AUUGGCAUCAAUGAAGGGUACGU-3' (SEQ ID NO:1258).
4. dsRNA or a salt thereof according to any one of claims 1 to 3, wherein the sense strand comprises at least 19 contiguous nucleotides that differ by no more than 3 nucleotides from the nucleotide sequence 5'-GUACCCUUCAUUGAUGCCAAU-3' (SEQ ID NO: 1168).
5. dsRNA or a salt thereof according to any one of claims 1 to 4, wherein the sense strand comprises at least 19 contiguous nucleotides that differ by no more than 2 nucleotides from the nucleotide sequence 5'-GUACCCUUCAUUGAUGCCAAU-3' (SEQ ID NO:1168).
6. dsRNA or a salt thereof according to any one of claims 1 to 5, wherein the sense strand comprises at least 19 contiguous nucleotides that differ by no more than 1 nucleotide from the nucleotide sequence 5'-GUACCCUUCAUUGAUGCCAAU-3' (SEQ ID NO: 1168).
7. The dsRNA or salt thereof according to any one of claims 1 to 6, wherein at least one of the nucleotide modifications is selected from the group consisting of a deoxynucleotide modification, a 3'-terminal deoxythymine (dT) nucleotide modification, a 2'-terminal deoxythymine (dT) nucleotide modification, a 2'-O-methyl nucleotide modification, a 2'-fluoro nucleotide modification, a 2'-deoxynucleotide modification, a locked nucleotide modification, an unlocked nucleotide modification, a conformationally constrained nucleotide modification, a constrained ethyl nucleotide modification, an abasic nucleotide modification, a 2'-amino-modified nucleotide modification, a 2'-O-allyl nucleotide modification, a 2'-C-alkyl nucleotide modification, a 2'-hydroxyl nucleotide modification, a 2'-methoxyethyl nucleotide modification, a 2'-O-alkyl nucleotide modification, morpholinonucleotide, phosphoramidate modification, non-natural base nucleotide modification, tetrahydropyran nucleotide modification, modification 1,5-anhydrohexitol nucleotide, cyclohexenyl nucleotide modification, phosphorothioate group-containing nucleotide modification, methylphosphonate group-containing nucleotide modification, 5'-phosphate-containing nucleotide modification, 5'-phosphate mimic-containing nucleotide modification, thermodestabilizing nucleotide modification, glycol nucleotide (GNA) modification, and 2-O-(N-methylacetamide) nucleotide modification, and combinations thereof.
8. dsRNA or a salt thereof according to any one of claims 1 to 6, wherein at least one of the nucleotide modifications is selected from the group consisting of a deoxynucleotide modification, a 2'-O-methyl-nucleotide modification, a 2'-fluoro-nucleotide modification, a 2'-deoxy-nucleotide modification, a glycol-nucleotide (GNA) modification, and a vinylphosphonate nucleotide modification, and combinations thereof.
9. dsRNA or a salt thereof according to any one of claims 1 to 6, wherein at least one of the nucleotide modifications is a thermally destabilizing nucleotide modification.
10. dsRNA or a salt thereof according to claim 9, wherein the thermally destabilizing modification of the nucleotide is selected from the group consisting of an abasic modification; a mismatch with the opposite nucleotide in the duplex; and a destabilizing modification of a sugar, a 2'-deoxy modification, an acyclic nucleotide, unlocked nucleic acids (UNA) and glycerol nucleic acid (GNA).
11. dsRNA or its salt according to any one of claims 1 to 10, wherein the length of the double-stranded region is 19 to 30 nucleotide pairs.
12. dsRNA or its salt according to claim 11, wherein the length of the double-stranded region is 19-25 nucleotide pairs.
13. dsRNA or its salt according to claim 11, wherein the length of the double-stranded region is 19-23 nucleotide pairs.
14. dsRNA or its salt according to claim 11, wherein the length of the double-stranded region is 23-27 nucleotide pairs.
15. dsRNA or its salt according to claim 11, wherein the length of the double-stranded region is 21-23 nucleotide pairs.
16. dsRNA or its salt according to any one of claims 1 to 15, wherein each chain independently has a length of no more than 30 nucleotides.
17. dsRNA or its salt according to any one of claims 1 to 16, wherein the length of the sense strand is 21 nucleotides and the length of the antisense strand is 23 nucleotides.
18. dsRNA or a salt thereof according to any one of claims 1 to 17, wherein at least one strand comprises a 3'-overhang of at least 1 nucleotide.
19. dsRNA or a salt thereof according to any one of claims 1 to 17, wherein at least one strand comprises a 3'-overhang of at least 2 nucleotides.
20. dsRNA or a salt thereof according to any one of claims 1 to 19, wherein the ligand is conjugated to the 3'-end of the sense strand of the dsRNA-based agent or a salt thereof.
21. dsRNA or its salt according to claim 20, wherein the ligand is a derivative of N-acetylgalactosamine (GalNAc).
22. dsRNA or a salt thereof according to claim 20 or 21, wherein the ligand is one or more GalNAc derivatives attached via a monovalent, divalent or trivalent branched linker.
23. dsRNA or its salt according to claim 21 or 22, wherein the ligand is 24. dsRNA or its salt according to claim 23, wherein the dsRNA or its salt is conjugated to a ligand as shown in the following scheme: and where X is O or S.
25. dsRNA or its salt according to claim 24, wherein X is O.
26. dsRNA or a salt thereof according to any one of claims 1 to 25, wherein the dsRNA or a salt thereof further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.
27. dsRNA or its salt according to claim 26, wherein the phosphorothioate or methylphosphonate internucleotide linkage is located at the 3'-end of one of the chains.
28. dsRNA or a salt thereof according to claim 27, wherein the chain is an antisense chain.
29. dsRNA or its salt according to claim 27, wherein the chain is a sense chain.
30. dsRNA or its salt according to claim 26, wherein the phosphorothioate or methylphosphonate internucleotide linkage is located at the 5'-end of one of the chains.
31. dsRNA or its salt according to claim 30, wherein the chain is an antisense chain.
32. dsRNA or its salt according to claim 30, wherein the chain is a sense chain.
33. dsRNA or its salt according to claim 26, wherein the phosphorothioate or methylphosphonate internucleotide linkage is located at both the 5'- and 3'-end of one of the chains.
34. dsRNA or its salt according to claim 33, wherein the chain is an antisense chain.
35. A cell containing dsRNA or its salt according to any one of claims 1 to 34.
36. A pharmaceutical composition for inhibiting the expression of the gene encoding the patatin-like phospholipase domain protein 3 (PNPLA3), comprising dsRNA or its salt according to any one of claims 1 to 34 and a pharmaceutically acceptable carrier.
37. A method for inhibiting in vitro expression of the patatin-like phospholipase domain protein 3 (PNPLA3) gene in a cell, comprising contacting the cell with dsRNA or a salt thereof according to any one of claims 1 to 34 or a pharmaceutical composition according to claim 36, thereby inhibiting expression of the PNPLA3 gene in the cell.
38. The method according to claim 37, wherein contacting the cell with dsRNA or a salt thereof inhibits the expression of PNPLA3 by at least 50, 60, 70, 80, 90 or 95%.
39. A method for treating a subject suffering from a disorder that can be helped by reducing the expression of patatin-like phospholipase domain encoding protein 3 (PNPLA3), comprising administering to the subject a therapeutically effective amount of dsRNA or a salt thereof according to any one of claims 1 to 34 or a pharmaceutical composition according to claim 36, thereby facilitating the cure of the subject suffering from a disorder that would benefit from reducing the expression of PNPLA3.
40. The method of claim 39, wherein the disorder is a PNPLA3-associated disorder.
41. The method of claim 40, wherein the disorder associated with PNPLA3 is selected from the group consisting of fatty liver disease (steatosis), non-alcoholic steatohepatitis (NASH), liver cirrhosis, liver fat accumulation, liver inflammation, hepatocellular necrosis, liver fibrosis, obesity, and non-alcoholic fatty liver disease (NAFLD).
42. The method according to claim 40, where the subject is a human being.
43. The method according to any one of paragraphs 39-42, wherein the dsRNA or its salt is administered to the subject subcutaneously.
44. The method according to any one of paragraphs 39-43, further comprising administering to the subject an additional therapeutic agent for treating a PNPLA3-associated disorder.
45. A method for inhibiting the expression of patatin-like phospholipase domain containing 3 (PNPLA3) in a subject, comprising administering to the subject dsRNA or a salt thereof according to any one of claims 1-34 or a pharmaceutical composition according to claim 6.
46. The method of claim 45, wherein the subject has a disorder associated with PNPLA3.
47. The method of claim 46, wherein the disorder associated with PNPLA3 is selected from the group consisting of fatty liver disease (steatosis), non-alcoholic steatohepatitis (NASH), liver cirrhosis, liver fat accumulation, liver inflammation, hepatocellular necrosis, liver fibrosis, obesity, and non-alcoholic fatty liver disease (NAFLD).
48. The method according to paragraph 45, where the subject is a human being.
49. The method according to any one of claims 45-48, wherein the dsRNA or salt thereof is administered to the subject subcutaneously.
50. The method according to any one of paragraphs 39-43, further comprising administering to the subject an additional therapeutic agent for treating a PNPLA3-associated disorder.
